Prices for more than 200 more items of medicines may be reduced by an average of 30%, predicts Petro Bahriy, chairman of the Association of Manufacturers of Medicines of Ukraine (AMPU).
“This work (to reduce drug prices) has not been completed yet, it is ongoing, and we are now working on the next 200-250 items of drugs that will also be reduced. It will not be reduced by all 30%: some will be reduced by 30%, some by 40%, some by 20%. This will be determined by the market situation,” he said at a press conference at the Ukraine Media Center on Friday.
He noted that if one manufacturer reduces the price of one molecule, a competitor will also be forced to reduce its price.
At the same time, Bagriy noted that price cuts will have a positive effect on patients, but will lead to “huge losses” for pharmaceutical plants.
“For example, if we are talking about Darnitsa, it is about one billion hryvnias that it will lose from the price reduction. Of course, this cannot but affect the company’s investment policy, salary payments, and even some layoffs are possible,” he said.
